Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 66% of modeled bridge. Strengths: Payer Diversity, Occupancy Rate. Risks: Revenue per Bed, Commercial Payer %. Risk-adjusted uplift: $1.0M (vs $1.5M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $587K | $587K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $565K | $16K | $581K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $90K | $267K | $357K | $1.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $19K | $19K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 31.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $147K | $294K | $440K | $587K | $587K | $587K | $587K |
| Denial Rate Reduction | $0 | $145K | $291K | $436K | $581K | $581K | $581K | $581K |
| A/R Days Reduction | $0 | $119K | $238K | $357K | $357K | $357K | $357K | $357K |
| Clean Claim Rate | $0 | $9K | $19K | $19K | $19K | $19K | $19K | $19K |
| Cumulative | $0 | $421K | $841K | $1.3M | $1.5M | $1.5M | $1.5M | $1.5M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.5M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 60% / 10.6x | 65% / 12.2x | 69% / 13.7x | 71% / 14.5x | 72% / 15.3x |
| 9.0x | 56% / 9.1x | 60% / 10.5x | 64% / 11.8x | 66% / 12.5x | 68% / 13.2x |
| 10.0x | 51% / 7.9x | 56% / 9.1x | 60% / 10.3x | 61% / 10.9x | 63% / 11.6x |
| 11.0x | 47% / 6.8x | 51% / 8.0x | 56% / 9.1x | 57% / 9.7x | 59% / 10.2x |
| 12.0x | 43% / 6.0x | 48% / 7.0x | 52% / 8.1x | 54% / 8.6x | 56% / 9.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 25% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.9x, adding 3.6 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $2.1M | — | $2.1M | 7.1% |
| Year 1 | $2.1M | +$1.0M | $3.2M | 10.8% |
| Year 2 | $2.2M | +$1.5M | $3.8M | 12.8% |
| Year 3 | $2.3M | +$1.5M | $3.8M | 13.0% |
| Year 4 | $2.3M | +$1.5M | $3.9M | 13.3% |
| Year 5 | $2.4M | +$1.5M | $4.0M | 13.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $294K | $440K | $587K | $705K |
| Denial Rate Reductio | $291K | $436K | $581K | $698K |
| A/R Days Reduction | $179K | $268K | $357K | $429K |
| Clean Claim Rate | $9K | $14K | $19K | $23K |
| Total | $772K | $1.2M | $1.5M | $1.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 86 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 7.1% | -9.6% | 1.0% | 7.1% | P75 |
| Net-to-Gross | 39.7% | 21.6% | 26.9% | 31.3% | P89 |
| Occupancy | 55.8% | 47.1% | 56.7% | 69.2% | P47 |
| Rev/Bed | $185K | $821K | $1.3M | $1.6M | P2 |
| Exp/Bed | $172K | $555K | $1.2M | $1.6M | P1 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.